EMA updates on activities, including COVID-19

5 October 2020
ema_building-credit_rob_acket

At the October 2020 meeting of the European Medicines Agency’s management board, the particular focus was on the Agency’s activities in response to the COVID-19 pandemic. This was Guido Rasi’s final board meeting as the EMA’s executive director before Emer Cooke takes the helm in mid-November.

Update on COVID-19 activities

The management board was updated that the first ‘ rolling review’ of data on a COVID-19 vaccine started.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical